- cross-posted to:
- [email protected]
- [email protected]
- cross-posted to:
- [email protected]
- [email protected]
cross-posted from: https://mander.xyz/post/11304633
Ozempic maker Novo Nordisk facing pressure as study finds $1,000 appetite suppressant can be made for just $5
I read the article and I don’t think it factors in the upfront cost of R&D, Compliance, etc, so that’s basically a fantasy number.
Those are the costs of doing business, and can be greatly exaggerated. And other counties produce profitable drugs even with price restrictions. We’re so accustomed to price gouging, that we don’t recognize it.
You’re probably right. It’s more than likely the cost per dose. Which is also what the $1000 figure represents.
Somehow they can justify selling it for $155 a dose (per month?) in other countries while still making a profit above the overhead and compliance costs.